product name AGK2
Description: AGK2 is a potent, and selective SIRT2 inhibitor. AGK 2 inhibited SIRT2 with IC50 value of 3.5 μM and slightly inhibited SIRT1 and 3 at concentrations over 40 μM. AGK 2 increased acetylation of tubulin heterodimers from bovine brain. In primary rat astrocytes, AGK-2 (35 μM) significantly inhibited astrocyte viability and proliferation and also inhibited astrocyte activation induced by beta amyloid 1-42 (Aβ 1-42).
References: Science. 2007 Jul 27;317(5837):516-9; Biochem Biophys Res Commun. 2012 Jan 6;417(1):468-72; Oncotarget. 2013 Dec;4(12):2354-65.
434.27
Formula
C23H13Cl2N3O2
CAS No.
304896-28-4
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 10 mg/mL (23.0 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
8% DMSO+30% PEG 300+ddH2O: ~1.5 mg/mL
Synonyms
other peoduct :
| In Vitro |
In vitro activity: In SIRT2-myc-expressing HeLa cells, AGK2 effectively inhibits the activity of SIRT2, and increases acetylated tubulin. AGK2 protects dopaminergic neurons from α-Syn–induced toxicity in primary midbrain cultures. AGK2 induces both necrosis and caspase-3-dependent apoptosis in C6 glioma cells. SIRT2 also decreases merlin-mutant viability of mouse schwann cells (MSCs) without substantially reducing wild-type MSC viability. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | In drosophila model of parkinsons disease, AGK2 rescues α-Syn–mediated toxicity and modify aggregation |
| Animal model | |
| Formulation & Dosage | |
| References | Science. 2007 Jul 27;317(5837):516-9; Oncotarget. 2013 Dec;4(12):2354-65. |
